Biological agents versus chemotherapy in the treatment of colorectal cancer

Abstract

Biological agents are commonly incorporated as an adjunct to cytotoxic chemotherapy in the treatment of patients with advanced colorectal cancer. In contrast to cytotoxic chemotherapy, biological agents have minimal single agent activity and are largely considered to be cytostatic. Recent data supports the use of either combination regimens with chemotherapy and/or biological therapy. Interest in combining biological agents of co-existing molecular pathways is the most recent strategic approach. However, with the advent of these novel therapies, questions have arisen regarding appropriate clinical indication and potential treatment-related toxicities. The role of biological agents in the treatment of colorectal cancer and their role in contrast to cytotoxic chemotherapy will be explored.